Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Is this the catalyst US tech gian needs?
Muse models may just be the spark that the rirm needed in AI model development.
stocks
ASX share plunges due to Iran related weakness
Despite headwinds our long-term outlook is unchanged.
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,112.80 | 5.80 | 0.06% |
| CAC 40 | 8,259.60 | 13.81 | 0.17% |
| DAX 40 | 23,803.95 | 3.04 | -0.01% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,600.53 | 2.95 | -0.03% |
| HKSE | 25,893.54 | 141.14 | 0.55% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,573.00 | 351.11 | -0.62% |
| NZX 50 Index | 12,988.58 | 192.86 | -1.46% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,927.00 | 15.20 | 0.17% |
| SSE Composite Index | 3,986.22 | 0.01 | -0.00% |